Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 4/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851173 | 0.85 | PDE2A (0.44) | GPR3PDE2AFFAR4FFAR1ABL1 | |
| SCHEMBL29954255 | 0.85 | PDE2A (0.44) | GPR3PDE2AFFAR4FFAR1ABL1 | |
| SCHEMBL29954904 | 0.81 | GPR3 (0.42) | GPR3FFAR4ABL1MAPTEPHX2 | |
| SCHEMBL326214 | 0.81 | GPR3 (0.42) | GPR3FFAR4ABL1MAPTEPHX2 | |
| SCHEMBL29957379 | 0.81 | GPR3 (0.42) | GPR3FFAR4ABL1MAPTEPHX2 | |
| SCHEMBL29554405 | 0.80 | FFAR4 (0.41) | GPR3FFAR4FFAR1ABL1 | |
| SCHEMBL3993839 | 0.80 | FFAR4 (0.41) | GPR3FFAR4FFAR1ABL1 | |
| SCHEMBL28961819 | 0.79 | GPR3 (0.43) | GPR3ABL1MAPTEPHX2CXCR2 | |
| SCHEMBL320667 | 0.79 | TUBB4A (0.46) | GPR3FFAR4ABL1 | |
| SCHEMBL29956393 | 0.79 | TUBB4A (0.46) | GPR3FFAR4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4626861-A1 | HERBICIDAL DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | GPR3 2831/4885PDE2A 2777/4885FFAR4 4863/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | GPR3 293/4885PDE2A 555/4885FFAR4 51/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | GPR3 1830/4885PDE2A 1039/4885FFAR4 3542/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GPR3 2180/4885PDE2A 4251/4885FFAR4 4456/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | GPR3 1278/4885PDE2A 4201/4885FFAR4 4141/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GPR3 2180/4885PDE2A 4251/4885FFAR4 4456/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | GPR3 1143/4885PDE2A 212/4885FFAR4 1638/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | GPR3 579/4885PDE2A 1465/4885FFAR4 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.